Medicare and its beneficiaries are paying significantly more for Stelara, Johnson & Johnson’s (NYSE:JNJ) popular biologic drug used to treat autoimmune diseases when obtained through pharmacies rather ...
The Food and Drug Administration has approved Celltrion's Steqeyma (ustekinumab-stba), a biosimilar to Johnson & Johnson's Stelara (ustekinumab), for subcutaneous injection or intravenous infusion in ...
Celltrion has obtained the Food and Drug Administration’s clearance for a new presentation of Steqeyma (ustekinumab-stba), a biosimilar to Stelara (ustekinumab), in a 45mg/0.5ml solution in a ...
Stelara (ustekinumab) is a prescription drug that treats autoimmune conditions such as plaque psoriasis. You typically inject it subcutaneously (under your skin) or receive it intravenously (directly ...
Fresenius Kabi, an Operating Company of Fresenius, and a leading provider of essential medicines and medical technologies, ...
55.2 percent of induction responder patients treated with STELARAat the start of maintenance were in symptomatic remission approximately four years later (at week 200), 96.4 percent without ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback